Abstract: The present disclosure relates to proteins comprising antigen binding sites that bind to human complement C2 (C2). The present disclosure also relates to methods of inhibiting complement activity in a subject as well as methods of treating or preventing complement-mediated disorders.
Type:
Application
Filed:
August 12, 2020
Publication date:
October 20, 2022
Applicant:
CSL Innovation Pty Ltd.
Inventors:
Matthew Hardy, Con Panousis, Rodrigo Morales
Abstract: A soluble complement receptor type 1 (sCR1) conjugate comprising a sCR1 variant and a) a protein comprising an antigen binding domain that binds to a target and inhibits signaling by or via the target; orb) a protein comprising an antigen binding domain that binds to a blood coagulation factor.
Abstract: The present disclosure relates to methods for inhibiting activation of ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
Type:
Application
Filed:
June 26, 2020
Publication date:
September 1, 2022
Applicants:
The University of Melbourne, Olivia Newton-John Cancer Research Institute, CSL INNOVATION PTY LTD
Inventors:
Andreas BEHREN, Jonathan CEBON, Marc Rigau CORTAL, Thomas Samuel FULFORD, Dale Ian GODFREY, Andrew HAMMET, Simone OSTROUSKA, Con PANOUSIS, Adam Peter ULDRICH
Abstract: The present disclosure relates to a method for reducing circulating neutrophils in a subject without causing sustained grade 3 or grade 4 neutropenia. The present disclosure also relates to methods for treating neutrophilic conditions with an antibody that inhibit G-CSF signalling. In particular, the present disclosure relates to methods of 5 treating neutrophilic dermatoses, such as hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP).
Type:
Application
Filed:
December 4, 2019
Publication date:
July 14, 2022
Applicant:
CSL Innovation Pty Ltd
Inventors:
Karen Lisa INGUANTI, Jolanta AIREY, Jagdev SIDHU, Michael TORTORICI, Theresa YURASZECK
Abstract: The present disclosure provides a method of treating a wasting disorder in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling. The present disclosure also provides a method of treating cancer cachexia in a subject suffering from cancer cachexia, the method comprising 5 administering to the subject a compound that inhibits VEGF-B signaling.
Type:
Application
Filed:
September 18, 2019
Publication date:
September 2, 2021
Applicants:
CSL Limited, CSL Innovation Pty Ltd, B-Creative Sweden AB
© 2024 Justia
